HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
Figure 4
Fenofibrate suppresses the development of cardiac hypertrophy and increases the expression of nuclear HMGB1 in the heart. (a) Mice were treated with saline or the same dose of fenofibrate (50 mg/kg via gavage) after operation for 4 weeks; nuclear HMGB1 levels in the hearts of the mice were analyzed by western blot, and histone H3 was used as the loading control. (b) Mice were treated as described above, and ANP, BNP, and -MHC gene expressions in mice were quantitatively analyzed by real-time PCR. All of the data are representative of at least three independent experiments, and the data in (b) are the mean ± SEM from five mice for each group. and as indicated in the comparisons. (c) Data showing echocardiographic measurements in mice treated as described above. IVS: interventricular wall thickness; LVEDD: left-ventricular end-diastolic dimension; LVESD: left-ventricular end-systolic dimension. Data are the mean ± SEM from three mice for each group. and , as indicated in the comparisons.
